Significance of Human Papilloma Virus genotyping in cervical cancer screening
Keywords:
HPV, Cervical cancer, Screening, Genotyping, Significance
Abstract
Background and Objectives: Detection of specific human papillomavirus (HPV) genotypes may be useful for identifying those women who are at lower and higher risk for cervical precancer and cancer .Cervical cancer is the most common cancer and leading cause of cancer deaths in women in developing countries. Therefore, the present study was undertaken with the aim of identifying the most frequent HPV genotypes associated with different cervical lesions.
Materials and Methods: The study was a retrospective cross-sectional study conducted over a period of one and a half years i.e. from January2015 to July 2016, on women attending obstetrics and gynaecology department of a tertiary care hospital. One hundred eighty three consecutive scrape samples or cervical brushings were collected from women presenting with any type of cervical lesions. DNA was extracted from the clinical sample using Hybribio DNA extraction kit. Hybribio HPV genoarray test kit was used to genotype the HPV risk groups.
Results: Out of 183 cervical brushings collected over a period of one and a half years, 22 (12%) were positive for HPV genotypes. Among the latter, HPV18 genotype was observed in 12(54.5%), HPV16 genotype in 3 (13.6%) and HPV53 genotype in 2(9.09%). One of the genotypes 68, 52, 39, 33 and 56 were present in rest of the samples.
Conclusion: Most common genotypes associated with cervical lesions in the present study were genotype 18 followed by 16 which shows that cervical cancer screening should rely on measuring the causal viral infection, oncogenic HPV, rather than the pleomorphic cellular changes caused by the infection.
Downloads
Download data is not yet available.
References
1. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003 Jan;16(1):1-17. [PubMed]
2. Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravichandran K. Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc. 2000 Feb;98(2):49-52. [PubMed]
3. Speich N, Schmitt C, Bollmann R, Bollmann M. Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol. 2004 Feb;53(Pt 2):125-8. DOI: 10.1099/jmm.0.05447-0.
4. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000 May 16;132(10):810-9.
5. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.
6. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005 Apr;6(4):204.
7. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep 17-23;366(9490):991-8.
8. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 Jan 13;88(1):63-73. [PubMed]
9. MolanoM, Van den Brule A, Plummer M, Weiderpass E, Poso H, Arslan A,et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population based, 5 years follow-up study. Am J Epidemiol 2003; 158:486-494. DOI: 10.1093/aje/kwg171.
10. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.
11. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. International agency for research on cancer. Multicenter Cervical cancer study group. Epidemiological classification of human papilloma virus types associated with cervical cancer. N Engl J Med 2003Feb6; 348:518-27. DOI: 10.1056/NEJMoa021641.
12. Spitzer M. Cervical screening adjuncts: recent advances. Am J Obstet Gynecol. 1998 Aug;179(2):544-56. [PubMed]
13. Duttagupta C, Sengupta S, Roy M, Senguota D, Bhatacharya P, et al. Are Muslim women less susceptible to oncogenic human papillomavirus infection. A study from rural eastern India. Int J Gynaecol Cancer 2004; 14(2):293-303.
14. Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V, Arora SK. Prevalence of high--risk human papillomavirus infections in women with benign cervical cytology: a hospital based study from North India. Indian J Cancer. 2006 Jul-Sep;43(3):110-6.
15. Basu P, Roychowdhury S, Bafna UD, Chaudhury S, Kothari S, Sekhon R, Saranath D, Biswas S, Gronn P, Silva I, Siddiqi M, Ratnam S. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):27-34.
16. Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006;94:171–5. [PubMed]
17. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98: 303–15.
18. De Mendez MT. Prevalence of Human Papillomavirus (HPV) Genotypes and Multiple Infections in Routine Cervical Cancer Screening in a Spanish Regional Population. SOJ Microbiol Infect Dis 2013;1(1):6. http://dx.doi.org/10.15226/sojmid.2013.00105.
19. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, Hernández P, Salmerón J, Hernández M. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001 Feb 1;91(3):412-20. [PubMed]
20. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278-85.
21. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019.
22. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun;62(3):147-72. doi: 10.3322/caac.21139. Epub 2012 Mar 14.
23. Trottier H, Franco EL . Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006; 12: S462-S472. [PubMed]
24. FrancoEL, Cuzick J. Cervical cancer screening following prophylactic humanpapillomavirus vaccination. Vaccine 2008; 26: A16-A23.
25. No JH, Kim MK, Jeon YT, Kim YB, Song YS. Human papillomavirus vaccine: widening the scope for cancer prevention. Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. [PubMed]
26. Castle PE. The potential utility of HPV genotyping in screening and clinical management. J Natl Compr Canc Netw. 2008 Jan;6(1):83-95. [PubMed]
2. Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravichandran K. Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc. 2000 Feb;98(2):49-52. [PubMed]
3. Speich N, Schmitt C, Bollmann R, Bollmann M. Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol. 2004 Feb;53(Pt 2):125-8. DOI: 10.1099/jmm.0.05447-0.
4. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000 May 16;132(10):810-9.
5. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.
6. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005 Apr;6(4):204.
7. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005 Sep 17-23;366(9490):991-8.
8. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 Jan 13;88(1):63-73. [PubMed]
9. MolanoM, Van den Brule A, Plummer M, Weiderpass E, Poso H, Arslan A,et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population based, 5 years follow-up study. Am J Epidemiol 2003; 158:486-494. DOI: 10.1093/aje/kwg171.
10. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.
11. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. International agency for research on cancer. Multicenter Cervical cancer study group. Epidemiological classification of human papilloma virus types associated with cervical cancer. N Engl J Med 2003Feb6; 348:518-27. DOI: 10.1056/NEJMoa021641.
12. Spitzer M. Cervical screening adjuncts: recent advances. Am J Obstet Gynecol. 1998 Aug;179(2):544-56. [PubMed]
13. Duttagupta C, Sengupta S, Roy M, Senguota D, Bhatacharya P, et al. Are Muslim women less susceptible to oncogenic human papillomavirus infection. A study from rural eastern India. Int J Gynaecol Cancer 2004; 14(2):293-303.
14. Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V, Arora SK. Prevalence of high--risk human papillomavirus infections in women with benign cervical cytology: a hospital based study from North India. Indian J Cancer. 2006 Jul-Sep;43(3):110-6.
15. Basu P, Roychowdhury S, Bafna UD, Chaudhury S, Kothari S, Sekhon R, Saranath D, Biswas S, Gronn P, Silva I, Siddiqi M, Ratnam S. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):27-34.
16. Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006;94:171–5. [PubMed]
17. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98: 303–15.
18. De Mendez MT. Prevalence of Human Papillomavirus (HPV) Genotypes and Multiple Infections in Routine Cervical Cancer Screening in a Spanish Regional Population. SOJ Microbiol Infect Dis 2013;1(1):6. http://dx.doi.org/10.15226/sojmid.2013.00105.
19. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, Hernández P, Salmerón J, Hernández M. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001 Feb 1;91(3):412-20. [PubMed]
20. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278-85.
21. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019.
22. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun;62(3):147-72. doi: 10.3322/caac.21139. Epub 2012 Mar 14.
23. Trottier H, Franco EL . Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006; 12: S462-S472. [PubMed]
24. FrancoEL, Cuzick J. Cervical cancer screening following prophylactic humanpapillomavirus vaccination. Vaccine 2008; 26: A16-A23.
25. No JH, Kim MK, Jeon YT, Kim YB, Song YS. Human papillomavirus vaccine: widening the scope for cancer prevention. Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. [PubMed]
26. Castle PE. The potential utility of HPV genotyping in screening and clinical management. J Natl Compr Canc Netw. 2008 Jan;6(1):83-95. [PubMed]
CITATION
DOI: 10.17511/jopm.2016.i03.07
How to Cite
Sharma, P., Sharma, S., & Mrs Arti. (1). Significance of Human Papilloma Virus genotyping in cervical cancer screening. Tropical Journal of Pathology and Microbiology, 2(3), 120-124. https://doi.org/10.17511/jopm.2016.i03.07
Section
Original Article
OAI - Open Archives Initiative
